Fairmount Healthcare Fund II L.P.
Insider CIK 1769651 · CBIO Director, 10% owner · VRDN Director, 10% owner · SYRE Director, 10% owner · KRSA Director, 10% owner · JBIO Director, 10% owner · DMRA Director, 10% owner · ZBIO Director · APGE Director · ORKA Director, 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| KRSA Korsana Biosciences, Inc. | A Award deriv | 2026-09-09 | 2026-09-10 | 48,445 | — | $0 | 48,445 | SEC↗ |
| KRSA Korsana Biosciences, Inc. | A Award deriv | 2026-09-09 | 2026-09-10 | 48,445 | — | $0 | 48,445 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 7,657 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 14,461 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 47,758 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 10,370 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 6,743,321 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer | 2026-09-03 | 2026-09-03 | 51,166 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer | 2026-09-03 | 2026-09-03 | 340,855 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer | 2026-09-03 | 2026-09-03 | 51,166 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 7,657 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 14,461 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 10,370 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 47,758 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 6,743,321 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer | 2026-09-03 | 2026-09-03 | 51,166 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer | 2026-09-03 | 2026-09-03 | 51,166 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer | 2026-09-03 | 2026-09-03 | 340,855 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | M Exercise deriv | 2026-08-07 | 2026-08-11 | 10,370 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | M Exercise deriv | 2026-08-07 | 2026-08-11 | 31,838 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | M Exercise | 2026-08-07 | 2026-08-11 | 10,370 | $43.85 | $454.7K | 340,855 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | M Exercise | 2026-08-07 | 2026-08-11 | 31,838 | $17.00 | $541.2K | 330,485 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | M Exercise deriv | 2026-08-07 | 2026-08-11 | 10,370 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | M Exercise deriv | 2026-08-07 | 2026-08-11 | 31,838 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | M Exercise | 2026-08-07 | 2026-08-11 | 10,370 | $43.85 | $454.7K | 340,855 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | M Exercise | 2026-08-07 | 2026-08-11 | 31,838 | $17.00 | $541.2K | 330,485 | SEC↗ |
| CBIO CRESCENT BIOPHARMA, INC. | P Buy deriv | 2026-07-16 | 2026-07-20 | 525,897 | $14.50 | $7.63M | 2,294,037 | SEC↗ |
| CBIO CRESCENT BIOPHARMA, INC. | P Buy | 2026-07-16 | 2026-07-20 | 853,450 | $14.50 | $12.38M | 3,601,316 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | C Conversion deriv | 2026-07-01 | 2026-07-01 | 42,641 | — | $0 | 94,497 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | C Conversion | 2026-07-01 | 2026-07-01 | 3,553,410 | — | $0 | 4,685,364 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | S Sale | 2026-07-01 | 2026-07-01 | 3,553,410 | $84.43 | $300.01M | 1,131,954 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | C Conversion deriv | 2026-06-23 | 2026-06-23 | 16,667 | — | $0 | 0 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | S Sale | 2026-06-23 | 2026-06-23 | 4,684,781 | $85.31 | $399.66M | 0 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | C Conversion | 2026-06-23 | 2026-06-23 | 666,680 | — | $0 | 4,684,781 | SEC↗ |
| JBIO Jade Biosciences, Inc. | A Award deriv | 2026-06-09 | 2026-06-11 | 34,843 | — | $0 | 34,843 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | A Award deriv | 2026-06-02 | 2026-06-03 | 9,136 | — | $0 | 9,136 | SEC↗ |
| CBIO CRESCENT BIOPHARMA, INC. | A Award deriv | 2026-06-02 | 2026-06-03 | 11,050 | — | $0 | 11,050 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | A Award deriv | 2026-05-27 | 2026-05-29 | 8,026 | — | $0 | 8,026 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | P Buy | 2026-05-11 | 2026-05-13 | 1,176,470 | $17.00 | $20.00M | 5,090,928 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | P Buy | 2026-03-31 | 2026-04-01 | 150,000 | $20.00 | $3.00M | 2,359,025 | SEC↗ |
| DMRA Damora Therapeutics, Inc. | A Award deriv | 2026-03-23 | 2026-03-25 | 37,313 | — | $0 | 37,313 | SEC↗ |
| GLTO Galecto, Inc. | M Exercise deriv | 2026-02-09 | 2026-02-12 | 2,904 | — | $0 | 574 | SEC↗ |
| GLTO Galecto, Inc. | M Exercise deriv | 2026-02-09 | 2026-02-12 | 5,809 | — | $0 | 1,148 | SEC↗ |
| GLTO Galecto, Inc. | M Exercise | 2026-02-09 | 2026-02-12 | 2,904,000 | — | $0 | 2,904,000 | SEC↗ |
| GLTO Galecto, Inc. | M Exercise | 2026-02-09 | 2026-02-12 | 5,809,000 | — | $0 | 5,809,000 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | S Sale | 2026-01-22 | 2026-01-22 | 1,750,000 | $76.30 | $133.53M | 298,647 | SEC↗ |
| CBIO CRESCENT BIOPHARMA, INC. | P Buy deriv | 2025-12-04 | 2025-12-08 | 131,434 | $13.41 | $1.76M | 1,768,140 | SEC↗ |
| CBIO CRESCENT BIOPHARMA, INC. | P Buy | 2025-12-04 | 2025-12-08 | 1,360,000 | $13.41 | $18.24M | 2,747,866 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | P Buy | 2025-10-23 | 2025-10-27 | 454,545 | $22.00 | $10.00M | 3,914,458 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | P Buy | 2025-10-07 | 2025-10-09 | 316,219 | $19.00 | $6.01M | 2,209,025 | SEC↗ |
| JBIO Jade Biosciences, Inc. | A Award deriv | 2025-10-06 | 2025-10-08 | 855,047 | $9.14 | $7.82M | 855,047 | SEC↗ |
| JBIO Jade Biosciences, Inc. | A Award | 2025-10-06 | 2025-10-08 | 1,333,126 | $9.14 | $12.18M | 1,897,677 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | A Award | 2025-09-17 | 2025-09-19 | 333,340 | $15.00 | $5.00M | 1,131,954 | SEC↗ |
| CBIO GLYCOMIMETICS INC | A Award deriv | 2025-06-23 | 2025-06-23 | 9,023 | — | $0 | 9,023 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise deriv | 2025-06-10 | 2025-06-11 | 12,500 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | A Award deriv | 2025-06-10 | 2025-06-12 | 18,500 | — | $0 | 18,500 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise | 2025-06-10 | 2025-06-11 | 12,500 | $12.31 | $153.9K | 3,459,913 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise deriv | 2025-06-09 | 2025-06-11 | 1,600 | — | $0 | 0 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | M Exercise | 2025-06-09 | 2025-06-11 | 1,600 | $7.80 | $12.5K | 3,447,413 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | A Award deriv | 2025-06-02 | 2025-06-03 | 17,500 | — | $0 | 17,500 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | A Award deriv | 2025-05-29 | 2025-06-02 | 25,000 | — | $0 | 25,000 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | A Award deriv | 2025-05-29 | 2025-06-02 | 25,000 | — | $0 | 25,000 | SEC↗ |
| JBIO Jade Biosciences, Inc. | A Award deriv | 2025-04-29 | 2025-05-01 | 23,017 | — | $0 | 23,017 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | M Exercise deriv | 2024-11-19 | 2024-11-21 | 160 | — | $0 | 0 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | M Exercise | 2024-11-19 | 2024-11-21 | 160,000 | — | $0 | 798,614 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-16 | 357,143 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-16 | 2,614,287 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-16 | 6,163,236 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-16 | 2,195,871 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-17 | 357,143 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-17 | 2,195,871 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-17 | 6,163,236 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion deriv | 2024-09-16 | 2024-09-17 | 2,614,287 | — | $0 | 0 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-16 | 41,130 | — | $0 | 41,140 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-16 | 252,890 | — | $0 | 294,020 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-16 | 709,794 | — | $0 | 1,003,814 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | P Buy | 2024-09-16 | 2024-09-16 | 300,000 | $17.00 | $5.10M | 1,604,891 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-16 | 301,077 | — | $0 | 1,304,891 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | P Buy | 2024-09-16 | 2024-09-17 | 300,000 | $17.00 | $5.10M | 1,892,806 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-17 | 41,130 | — | $0 | 329,045 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-17 | 252,890 | — | $0 | 581,935 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-17 | 301,077 | — | $0 | 1,592,806 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | C Conversion | 2024-09-16 | 2024-09-17 | 709,794 | — | $0 | 1,291,729 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | P Buy | 2024-09-13 | 2024-09-17 | 1,600,000 | $18.75 | $30.00M | 3,445,813 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | A Award deriv | 2024-09-12 | 2024-09-16 | 37,000 | — | $0 | 37,000 | SEC↗ |
| ZBIO Zenas BioPharma, Inc. | A Award deriv | 2024-09-12 | 2024-09-17 | 37,000 | — | $0 | 37,000 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | A Award deriv | 2024-09-11 | 2024-09-13 | 160 | $23000.00 | $3.68M | 160 | SEC↗ |
| ORKA Oruka Therapeutics, Inc. | A Award | 2024-09-11 | 2024-09-13 | 275,000 | $23.00 | $6.33M | 638,614 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | M Exercise deriv | 2024-04-25 | 2024-04-25 | 90,992 | — | $0 | 346,045 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | M Exercise | 2024-04-25 | 2024-04-25 | 3,639,680 | — | $0 | 4,018,101 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | J Other deriv | 2024-03-28 | 2024-04-01 | 221,426 | — | $0 | 6,743,321 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | J Other deriv | 2024-03-28 | 2024-04-01 | 221,426 | — | $0 | 0 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | J Other deriv | 2024-03-28 | 2024-04-01 | 21,999 | — | $0 | 0 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | J Other deriv | 2024-03-28 | 2024-04-01 | 21,999 | — | $0 | 133,191 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | J Other | 2024-03-28 | 2024-04-01 | 55,913 | — | $0 | 2,048,647 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | J Other | 2024-03-28 | 2024-04-01 | 55,913 | — | $0 | 0 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | J Other | 2024-03-28 | 2024-04-01 | 5,859 | — | $0 | 1,845,813 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | J Other | 2024-03-28 | 2024-04-01 | 5,859 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | J Other | 2024-01-29 | 2024-01-31 | 51,166 | — | $0 | 51,166 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | J Other | 2024-01-29 | 2024-01-31 | 892,529 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | J Other | 2024-01-29 | 2024-01-31 | 51,166 | — | $0 | 51,166 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | P Buy | 2024-01-22 | 2024-01-24 | 476,190 | $21.00 | $10.00M | 1,839,954 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | J Other | 2023-12-29 | 2023-12-29 | 3,435,480 | — | $0 | 0 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | J Other | 2023-12-29 | 2023-12-29 | 406,038 | — | $0 | 406,038 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | J Other | 2023-12-29 | 2023-12-29 | 406,038 | — | $0 | 406,038 | SEC↗ |
| SYRE Spyre Therapeutics, Inc. | A Award deriv | 2023-12-07 | 2023-12-11 | 16,667 | $600.00 | $10.00M | 16,667 | SEC↗ |
| AGLE Spyre Therapeutics, Inc. | C Conversion deriv | 2023-11-24 | 2023-11-28 | 85,887 | — | $0 | 0 | SEC↗ |
| AGLE Spyre Therapeutics, Inc. | C Conversion | 2023-11-24 | 2023-11-28 | 3,435,480 | — | $0 | 3,435,480 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | A Award deriv | 2023-10-30 | 2023-11-01 | 48,463 | $825.37 | $40.00M | 48,463 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | A Award deriv | 2023-07-13 | 2023-07-17 | 47,758 | — | $0 | 47,758 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | A Award deriv | 2023-07-13 | 2023-07-17 | 47,758 | — | $0 | 47,758 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | P Buy | 2023-07-13 | 2023-07-17 | 892,529 | $17.00 | $15.17M | 892,529 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | P Buy | 2023-07-13 | 2023-07-17 | 1,992,734 | $17.00 | $33.88M | 1,992,734 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | P Buy | 2023-07-13 | 2023-07-17 | 55,913 | $17.00 | $950.5K | 55,913 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | P Buy | 2022-08-17 | 2022-08-19 | 425,531 | $23.50 | $10.00M | 1,363,764 | SEC↗ |
| VRDN Viridian Therapeutics, Inc | P Buy | 2021-09-21 | 2021-09-23 | 909,000 | $11.00 | $10.00M | 938,233 | SEC↗ |
| MGEN MIRAGEN THERAPEUTICS, INC. | P Buy deriv | 2020-10-30 | 2020-10-30 | 5,494 | $465.96 | $2.56M | 21,999 | SEC↗ |
| MGEN MIRAGEN THERAPEUTICS, INC. | P Buy deriv | 2020-10-30 | 2020-10-30 | 28,843 | $465.96 | $13.44M | 111,192 | SEC↗ |
| MGEN MIRAGEN THERAPEUTICS, INC. | J Other deriv | 2020-10-27 | 2020-10-29 | 16,505 | — | $0 | 16,505 | SEC↗ |
| MGEN MIRAGEN THERAPEUTICS, INC. | J Other deriv | 2020-10-27 | 2020-10-29 | 82,349 | — | $0 | 82,349 | SEC↗ |
| MGEN MIRAGEN THERAPEUTICS, INC. | J Other | 2020-10-27 | 2020-10-29 | 438,502 | — | $0 | 438,502 | SEC↗ |
| MGEN MIRAGEN THERAPEUTICS, INC. | J Other | 2020-10-27 | 2020-10-29 | 87,891 | — | $0 | 87,891 | SEC↗ |